Efficacy and applications for PuraStat®use in the management of unselected gastrointestinal bleeding:A retrospective observational study  

作　　者：Raquel Ballester Conor Costigan Aoife Mary O'Sullivan Shreyashee Sengupta Deirdre McNamara 

机构地区：[1]Department of Gastroenterology,Tallaght University Hospital,Dublin D24,Ireland [2]Trinity Academic Gastroenterology Group,School of Medicine-Trinity College Dublin,Dublin D2,Ireland

出　　处：《World Journal of Gastrointestinal Endoscopy》2025年第3期12-20,共9页世界胃肠内镜杂志(英文)

摘　　要：BACKGROUND Hemostatic powders have been used as primary or salvage therapy to control gastrointestinal bleeding in a number of scenarios.PuraStat®is a novel,selfassembling peptide gel that has properties that differ from hemostatic powders.It is transparent,can be used in narrow spaces and combined with other modalities.Also,it is pre-filled in a syringe ready to use and easy to handle and deliver.PuraStat®has been shown to be effective and safe in treating gastrointestinal bleeding lesions.But,its role as a hemostatic agent in all bleeding indications remains to be clarified.AIM To evaluate PuraStat®efficacy and its applications,feasibility and safety in treating gastrointestinal bleeding lesions.METHODS We performed a retrospective single-centre analysis of all consecutive patients with gastrointestinal bleeding,that required endoscopic treatment and where PuraStat®was applied,from June 2020 to October 2022.Demographics,biochemical,endoscopic,endoscopist assessment and outcome data were collected.We analysed the whole cohort and the subgroup with upper gastrointestinal bleeding.The primary outcome was to evaluate the efficacy of PuraStat®at achieving initial hemostasis.The patients were followed-up for 30 days after the episode of bleeding.RESULTS In total 45 patients were included,and 17/45(37.8%)females.The mean age was 65.8 years.Charlson score was>2 in 27/45(60%)and 26/45(57.8%)required transfusion.The procedures were gastroscopy(77.8%),colonoscopy(15.5%),endoscopic retrograde cholangiopancreatography(4.4%)and enteroscopy(2.2%).The most common bleeding lesion was peptic ulcer(33.3%).PuraStat®was used alone in 36%of the cases.One hundred percent achieved initial hemostasis and no complications were documented.There were no significant differences between the use of PuraStat®alone or in combination in terms of re-bleeding(P=0.64)or mortality(P=0.69).In 46.6%of cases,the reason for applying PuraStat®was as addition to standard of care,in 35.5%as an alternative because standard of care was not possible

关 键 词：PuraStat® Endoscopic hemostatic agent Hemostatic gel Hemostatic techniques Endoscopic hemostasis Gastrointestinal hemorrage 

分 类 号：R57[医药卫生—消化系统]